CN117106070B - 抗水痘-带状疱疹病毒的抗体 - Google Patents

抗水痘-带状疱疹病毒的抗体 Download PDF

Info

Publication number
CN117106070B
CN117106070B CN202311089088.4A CN202311089088A CN117106070B CN 117106070 B CN117106070 B CN 117106070B CN 202311089088 A CN202311089088 A CN 202311089088A CN 117106070 B CN117106070 B CN 117106070B
Authority
CN
China
Prior art keywords
seq
vzv
variable region
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311089088.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN117106070A (zh
Inventor
廖化新
王月明
郑伟宏
李嘉祺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai Tainuo Maibo Pharmaceutical Co ltd
Original Assignee
Zhuhai Tainuo Maibo Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai Tainuo Maibo Pharmaceutical Co ltd filed Critical Zhuhai Tainuo Maibo Pharmaceutical Co ltd
Priority to CN202311089088.4A priority Critical patent/CN117106070B/zh
Publication of CN117106070A publication Critical patent/CN117106070A/zh
Application granted granted Critical
Publication of CN117106070B publication Critical patent/CN117106070B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202311089088.4A 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体 Active CN117106070B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311089088.4A CN117106070B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202311089088.4A CN117106070B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN201911095151.9A CN112778413B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201911095151.9A Division CN112778413B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体

Publications (2)

Publication Number Publication Date
CN117106070A CN117106070A (zh) 2023-11-24
CN117106070B true CN117106070B (zh) 2024-06-11

Family

ID=75749734

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202311089088.4A Active CN117106070B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN202311088952.9A Active CN117106068B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN202311089485.1A Active CN117106071B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN202311089024.4A Active CN117106069B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN201911095151.9A Active CN112778413B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202311088952.9A Active CN117106068B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN202311089485.1A Active CN117106071B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN202311089024.4A Active CN117106069B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体
CN201911095151.9A Active CN112778413B (zh) 2019-11-11 2019-11-11 抗水痘-带状疱疹病毒的抗体

Country Status (6)

Country Link
US (1) US12491386B2 (enExample)
EP (1) EP4063383A4 (enExample)
JP (1) JP7689955B2 (enExample)
CN (5) CN117106070B (enExample)
PH (1) PH12022551151A1 (enExample)
WO (1) WO2021093639A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106070B (zh) * 2019-11-11 2024-06-11 珠海泰诺麦博制药股份有限公司 抗水痘-带状疱疹病毒的抗体
CN117683121B (zh) * 2024-01-30 2024-04-16 北京百普赛斯生物科技股份有限公司 抗水痘-带状疱疹病毒抗体及其应用
CN119192349A (zh) * 2024-07-18 2024-12-27 北京市延庆区疾病预防控制中心 用于检测黄连素抗性病毒的试剂及方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321249A2 (en) * 1987-12-15 1989-06-21 Toa Nenryo Kogyo Kabushiki Kaisha Agent for and method of diagnosis of varicella zoster virus infection
CN104513813A (zh) * 2013-09-29 2015-04-15 上海满益科技有限公司 一种带状疱疹病毒的制备方法
WO2015115767A1 (ko) * 2014-01-28 2015-08-06 연세대학교 원주산학협력단 수두대상포진 바이러스의 당단백질 ε를 발현하는 인간 세포를 이용한 수두대 상포진 바이러스에 대한 면역력 진단 방법
CN106279378A (zh) * 2016-08-05 2017-01-04 北京市华信行生物科技有限公司 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1995031546A1 (en) 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6528066B1 (en) * 1999-09-14 2003-03-04 University Of Iowa Research Foundation Variant varicella-zoster viruses and methods of use
BRPI0807084A2 (pt) * 2007-02-06 2014-04-29 Ribovax Biotechnologies Sa Anticorpos específicos para o virus varicela zoster
CN102517302A (zh) * 2011-12-28 2012-06-27 中国人民解放军军事医学科学院野战输血研究所 一种重组表达水痘-带状疱疹病毒截短型糖蛋白e的方法及其应用
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
JP6367783B2 (ja) * 2015-11-26 2018-08-01 田中貴金属工業株式会社 水痘帯状疱疹ウイルス検出用免疫クロマト分析装置
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107760690B (zh) * 2017-10-25 2018-08-28 珠海泰诺麦博生物技术有限公司 一种高通量全人源抗体的制备方法及应用
US11147870B2 (en) * 2018-04-25 2021-10-19 Emory University Specific binding agents to varicella-zoster virus and uses related thereto
CN109085354B (zh) * 2018-07-25 2021-07-23 武汉生命科技股份有限公司 水痘-带状疱疹病毒中和抗体的检测试剂盒及其检测方法
CN117106070B (zh) * 2019-11-11 2024-06-11 珠海泰诺麦博制药股份有限公司 抗水痘-带状疱疹病毒的抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0321249A2 (en) * 1987-12-15 1989-06-21 Toa Nenryo Kogyo Kabushiki Kaisha Agent for and method of diagnosis of varicella zoster virus infection
CN104513813A (zh) * 2013-09-29 2015-04-15 上海满益科技有限公司 一种带状疱疹病毒的制备方法
WO2015115767A1 (ko) * 2014-01-28 2015-08-06 연세대학교 원주산학협력단 수두대상포진 바이러스의 당단백질 ε를 발현하는 인간 세포를 이용한 수두대 상포진 바이러스에 대한 면역력 진단 방법
CN106279378A (zh) * 2016-08-05 2017-01-04 北京市华信行生物科技有限公司 水痘带状疱疹病毒gE抗原及其在检测抗水痘带状疱疹病毒抗体中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
水痘-带状疱疹免疫球蛋白研究进展;王敏力;沈琦;;中国生物制品学杂志;20070920(09);全文 *
水痘-带状疱疹病毒主要衣壳蛋白ORF40单克隆抗体的制备及初步应用;蔡琳俐;王玮;付文锟;潘德全;叶江辉;朱桦;程通;夏宁邵;;中国免疫学杂志;20190512(09);全文 *

Also Published As

Publication number Publication date
CN117106070A (zh) 2023-11-24
EP4063383A4 (en) 2024-01-17
CN117106069A (zh) 2023-11-24
US12491386B2 (en) 2025-12-09
CN117106071A (zh) 2023-11-24
CN112778413B (zh) 2023-09-22
CN117106071B (zh) 2024-08-27
EP4063383A1 (en) 2022-09-28
JP2023500387A (ja) 2023-01-05
CN117106068B (zh) 2024-04-16
PH12022551151A1 (en) 2023-10-02
CN112778413A (zh) 2021-05-11
WO2021093639A1 (zh) 2021-05-20
JP7689955B2 (ja) 2025-06-09
US20230192817A1 (en) 2023-06-22
CN117106069B (zh) 2024-06-11
CN117106068A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
ES2539751T3 (es) Anticuerpo monoclonal capaz de unirse con epítopo discontinuo específico que aparece en la región AD1 de la glucoproteína gB de citomegalovirus humano, y fragmento de unión a antígeno del mismo
IL295310A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021180110A1 (zh) 抗basigin人源化抗体用于制备治疗新型冠状病毒肺炎药物的应用
CN117106070B (zh) 抗水痘-带状疱疹病毒的抗体
JP7463366B2 (ja) 新規の抗ジカウイルス抗体及びその使用
EP4417621A1 (en) Design and application of fully human antibody for neutralizing respiratory syncytial virus
JP2024544936A (ja) 組成物
WO2022065445A1 (ja) ＳＡＲＳ－ＣｏＶ－２中和抗体又はその断片
US20210139564A1 (en) Methods and compositions for treating yellow fever
KR20220121820A (ko) 인간 사이토메갈로바이러스에 대한 항체 및 이의 용도
JP7653537B2 (ja) 抗水痘帯状疱疹ウイルスの抗体およびその使用
JP2010517557A (ja) 水痘帯状疱疹ウイルスに特異的な抗体
WO2022143815A1 (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN111153990B (zh) 针对Echo30的单克隆抗体、制备方法及其应用
EP4378951A1 (en) General affinity epitope polypeptide for human rhinovirus, and antibody and uses thereof
CN115087667B (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
CN107286237A (zh) 一种抗丙型肝炎病毒抗体的获取以及应用
CN119909167A (zh) 一种包含抗ccr8抗体的药物组合物及其用途
CN120535614A (zh) 抗RSV pre-F蛋白的抗体及其应用
CN119421953A (zh) 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段
CN115141270A (zh) 特异性结合新型冠状病毒的抗体
CN118871461A (zh) 组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant